Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina

Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a decreas...

Descripción completa

Detalles Bibliográficos
Autores principales: Giorgi, Mariano Anibal, Caroli, Christian, Giglio, Norberto Damian, Micone, Paula, Aiello, Eleonora, Vulcano, Cristina, Blanco, Julia, Donato, Bonnie, Quevedo, Joaquin Mould
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480270/
https://www.ncbi.nlm.nih.gov/pubmed/26112219
http://dx.doi.org/10.1186/s13561-015-0052-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480270/
https://www.ncbi.nlm.nih.gov/pubmed/26112219
http://dx.doi.org/10.1186/s13561-015-0052-8

Ejemplares similares